US2019247512A1PendingUtilityA1
Bifunctional polypeptides
Est. expiryMay 20, 2029(~2.8 yrs left)· nominal 20-yr term from priority
A61P 35/02A61P 37/00A61P 35/00A61P 43/00A61P 31/04A61P 9/00C07K 2317/73C07K 2319/33A61K 47/6425C07K 2317/622C07K 14/7051C07K 16/46A61K 47/6849A61K 38/00C07K 16/2809A61K 39/00114C07K 14/54
64
PatentIndex Score
0
Cited by
0
References
0
Claims
Abstract
A bifunctional polypeptide comprising a specific binding partner for a peptide-MHC epitope, such as an antibody or T cell receptor, and an immune effector, such as an antibody or a cytokine, the immune effector part being linked to the N-terminus of the peptide-MHC binding part.
Claims
exact text as granted — not AI-modified1 .- 13 . (canceled)
14 . A bifunctional molecule, comprising:
a heterodimeric αβ T-Cell Receptor (αβTCR) or a single chain T-Cell Receptor (scTCR) comprising a TCR α or TCR β constant region, wherein the αβ TCR or the scTCR binds specifically to a given pMHC epitope, and (ii) an immune effector polypeptide, wherein: the N-terminus of the α chain or the β chain of the αβ TCR, or the N-terminus of the scTCR, is linked to the C-terminus of the of the immune effector polypeptide, and the effector polypeptide is a cytokine which modulates lymphocyte immunosuppressive or immunostimulatory activity.
15 . The bifunctional molecule of claim 14 , wherein the cytokine is selected from the group consisting of: IL-1, IL-la, IL-3, IL-4, IL-5, IL-6, IL-7, IL-10, IL-11, IL-12, IL-13, IL-15, IL-21, IL-23, TGF-β, IFN-γ, and TNFα.
16 . The bifunctional molecule of claim 15 , wherein the cytokine is IL-4.
17 . The bifunctional molecule of claim 15 , wherein the cytokine is IL-13.
18 . The bifunctional molecule of claim 15 , wherein the cytokine is TNF-α.
19 . The bifunctional molecule of claim 15 , wherein the cytokine is IFN-γ.Join the waitlist — get patent alerts
Track US2019247512A1 — get alerts on status changes and closely related new filings.
We store only your email — no account needed. See our privacy policy.